477.
Gottlieb JA, Baker LH, O’Bryan RM, et al. Adriamycin used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep (Part 3) 1975;6:271–282.
478.
Blum RH, Corson JM, Wilson RE, et al. Successful treatment of metastatic sarcomas with cyclophosphamide, Adriamycin, and DTIC (CAD). Cancer 1980;46:1722–1726.
479.
Piver MS, DeEulis TG, Lele SB, et al. Cyclophosphamide, vincristine, adriamycin, and dimethyltriazenoimidazole carboxamide (CYVADIC) for sarcomas of the female genital tract. Gynecol Oncol 1981;14:319–323.
480.
Pearl ML, Inagami M, McCauley DL, et al. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecologic sarcomas. Int J Gynecol Cancer 2002;12:745–748.
481.
Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma. J Clin Oncol 2002;20:2824–2831.
482.
Nordal RN, Kjørstad KE, Stenwig AE, et al. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus: a survey of patients treated in the Norwegian Radium Hospital 1976–1985. Int J Gynecol Cancer 1993;3:110–115.
483.
Berchuck A, Rubin SC, Hoskins WJ, et al. Treatment of endometrial stromal tumors. Gynecol Oncol 1990;36:60–65.
484.
Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000;79:47–53.
485.
Homesley HD, Filiaci V, Markman M, et al. Gynecologic Oncology Group. Phase III trial of ifosfamide versus ifosfamide plus paclitaxel as first-line treatment of advanced or recurrent uterine carcinosarcoma (mixed mesodermal tumors): a Gynecologic Oncology Group study. J Clin Oncol 2007;25:526–531.
486.
Toyoshima M, Akahira J, Matsunaga G, et al. Clinical experiences with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma for the uterus. Gynecol Oncol 2004;94:774–778.
487.
Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1240–1245.
Caela Miller John C. Elkas
Human papillomavirus (HPV) infection is the causal agent of cervical cancer.
Screening programs are effective at decreasing the incidence of cervical cancer. Vaccines also help decrease the incidence of cervical cancer.